Kybernin P

Antithrombin III, the active ingredient in Kybernin P, is an antithrombin concentrate presented as an injection solution for intravenous use. It is used to treat patients with congenital antithrombin deficiency and to prevent thromboembolic events in those undergoing surgery, trauma, or experiencing heparin resistance.

GNH USA supplies Kybernin P as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, ensuring quality‑controlled delivery and regulatory compliance. The company provides cold‑chain logistics, batch‑specific documentation, and support for import licensing to meet the needs of global healthcare providers.

Kybernin P is indicated for conditions involving antithrombin deficiency and related coagulation disorders.

- Congenital antithrombin deficiency: restores antithrombin activity to reduce risk of spontaneous clot formation. - Surgical or trauma patients with antithrombin deficiency: prevents peri‑operative thromboembolic events. - Heparin resistance: serves as adjunct therapy to enhance anticoagulation when heparin alone is insufficient.

Kybernin P may be associated with infusion‑related and systemic adverse reactions.

Common Side Effects: - Fever: mild temperature elevation during or after infusion. - Chills or rigors: transient shaking sensations. - Hypotension: temporary drop in blood pressure. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal discomfort. - Injection site erythema: localized redness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate intervention. - Thrombotic events: paradoxical clot formation. - Hemolysis: destruction of red blood cells. - Severe bleeding: excessive hemorrhage. - Disseminated intravascular coagulation: widespread clotting and bleeding. - Transfusion‑related acute lung injury (TRALI): acute respiratory distress.

When using Kybernin P, clinicians should observe specific safety measures to minimize risks.

- Monitor antithrombin activity: measure plasma levels before and during therapy. - Assess bleeding risk: evaluate patient history of hemorrhage or concurrent anticoagulants. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Adjust dose in renal or hepatic impairment: consider reduced clearance. - Use caution with concomitant anticoagulants: increase monitoring of coagulation parameters. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kybernin P can interact with other agents that affect coagulation, requiring careful management.

Major Interactions (Avoid): - Heparin: combined use may markedly increase anticoagulant effect and bleeding risk. - Direct thrombin inhibitors (e.g., dabigatran): additive inhibition of thrombin can cause severe hemorrhage.

Moderate Interactions (Monitor Closely): - Warfarin or vitamin K antagonists: may require INR monitoring and dose adjustment. - Antiplatelet agents (aspirin, clopidogrel): heightened bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of gastrointestinal bleeding. - Fibrinolytic therapy (tPA): potential for excessive anticoagulation.